Mark Windfeld-Hansen

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised early-stage venture capital firm RPM Ventures as the lead investor for Firefly Aerospace's oversubscribed $175 million Series D.

Cooley advised Veritone, a company building human-centered enterprise artificial intelligence (AI) solutions, on the sale of its media agency, Veritone One, to Insignia Capital Group.

Cooley advised RTZ Systems, an information technology and services company, on its acquisition by CollabriOS Health, a new entity formed by Assured Healthcare Partners that brings together a suite of integrated technology infrastructure, including electronic health records, third-party administrator financial services, and care coordination solutions designed to help Programs of All-Inclusive Care for the Elderly (PACE) optimize workflows, streamline business processes and enhance overall center operations.

Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock.